Literature DB >> 6814636

Transient monoclonal gammopathy in hydralazine-induced lupus erythematosus.

S Freestone, L E Ramsay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6814636      PMCID： PMC1500553          DOI： 10.1136/bmj.285.6354.1536

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  3 in total

Review 1.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors:  H M Perry
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

2.  Frequency of pathological proteins (M-components) om 6,995 sera from an adult population.

Authors:  U Axelsson; R Bachmann; J Hällén
Journal:  Acta Med Scand       Date:  1966-02

3.  Hydrallazine in hypertension: is there a safe dose?

Authors:  R F Bing; G I Russell; H Thurston; J D Swales
Journal:  Br Med J       Date:  1980-08-02
  3 in total
  2 in total

1.  The lupus syndrome induced by hydralazine: a common complication with low dose treatment.

Authors:  H A Cameron; L E Ramsay
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-18

2.  Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.

Authors:  John P Bida; Robert A Kyle; Terry M Therneau; L Joseph Melton; Matthew F Plevak; Dirk R Larson; Angela Dispenzieri; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.